SIBTECH, INC.

Company Information

Company Name
SIBTECH, INC.
Address
115A Commerce Drive
Brookfield, CT, 06804-3400
Phone
n/a
URL
n/a
DUNS
966566465
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$3,747,983.00
25
SBIR Phase II
$4,565,997.00
5

Award List

  1. Targeted Delivery of Cardioprotective Drugs

    Amount: $385,462.00

    DESCRIPTION (provided by applicant): Myocardial infarction is a disabling disease, with infarct size being a major determinant of mortality. To limit infarct size and improve functional recovery, the ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. N/A

    Amount: $0.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  3. N/A

    Amount: $369,685.00

    N/A

    SBIR Phase II 2000 Department of Health and Human Services
  4. TARGETING ANGIOGENESIS WITH TOXIN-VEGF FUSION PROTEINS

    Amount: $99,296.00

    Not Available Ground Moving Target Indicator (GMTI) radar is designed to suppress returns from stationary background (clutter) in order to detect and track moving objects which would otherwise be obs ...

    SBIR Phase I 1999 Department of Health and Human Services
  5. TARGETING ANGIOGENESIS WITH TOXIN VEGF FUSION PROTEINS

    Amount: $0.00

    DESCRIPTION: (Applicant's Description) The overall goal of this proje ...

    SBIR Phase I 2001 Department of Health and Human Services
  6. TARGETING ANGIOGENESIS WITH TOXIN VEGF FUSION PROTEINS

    Amount: $545,700.00

    DESCRIPTION: (Applicant's Description) The overall goal of this proje ...

    SBIR Phase II 2001 Department of Health and Human Services
  7. VEGF-Based Delivery of Boron Therapeutics

    Amount: $99,510.00

    70733 Because the growth of primary tumor and metastatic lesions beyond a few millimeters requires formation of new blood vessels (angiogenesis), the targeted delivery of cytotoxic drugs to growin ...

    SBIR Phase I 2002 Department of Energy
  8. VEGF-Based Delivery of Boron Therapeutics

    Amount: $0.00

    70733S02-II Because the growth of primary tumor and metastatic lesions beyond a few millimeters requires formation of new blood vessels (angiogenesis), the targeted delivery of cytotoxic drugs to g ...

    SBIR Phase I 2003 Department of Energy
  9. Development of Monoclonal Antibody-Based Therapeutics for Treatment of Cancer

    Amount: $69,367.00

    Anti-cancer antibodies are potential molecular vehicles for targeted delivery of therapeutic and diagnostic agents to tumors and metastatic lesions. Currently,

    SBIR Phase I 2003 ArmyDepartment of Defense
  10. VEGF-Based Delivery of Boron Therapeutics

    Amount: $749,288.00

    70733S02-II Because the growth of primary tumor and metastatic lesions beyond a few millimeters requires formation of new blood vessels (angiogenesis), the targeted delivery of cytotoxic drugs to g ...

    SBIR Phase II 2003 Department of Energy

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government